Skip to main content

Advertisement

Log in

Primary Malignant Giant-Cell Tumor of Bone Has High Survival Rate

  • Bone and Soft Tissue Sarcomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Malignant giant-cell tumors (MGCT) comprise 2–9% of all giant-cell tumors (GCTs). The limited existing studies fail to distinguish primary, secondary, or postradiation cancers, making it difficult to design rational treatment strategies. This study compared malignant to benign GCTs and defined the clinical outcome of the patients in a large series of case-matched patients from a single institution.

Methods

Clinical, radiological, and outcome features were compared between 26 malignant and 244 benign GCTs treated in our institution. Five postradiation cancers were excluded. We also performed a 1:2 case-matched comparison of patients with malignant and benign disease.

Results

Distal femur (P = 0.019), proximal tibia (P = 0.032), and distal tibia (P = 0.049) had a higher frequency of MGCT. Campanacci stage 1 tumors had a low probability of malignancy (P = 0.017). MGCT were less likely to have aneurysmal bone cyst changes. The 5-year recurrence-free status probability was 80% for malignant and 91% for benign cases in matched groups. The difference in the recurrence rate between benign and malignant groups was not statistically significant (P = 0.24). Functional impairment and limited activity were greater in MGCT patients than in benign GCT patients, whether treated by resection/amputation or curettage/cryosurgery.

Conclusions

We found that malignant and benign GCT have similar epidemiology and that recurrence was higher in MGCT (20 v 9%). Local recurrence for MGCT was not statistically different for excision versus intralesional therapy, but there was little statistical power. Finally, the 16% mortality for patients with MGCT suggests low-grade malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Jaffe HL, Lichtenstein L, Portis RB. Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol. 1940;30:993–1031.

    Google Scholar 

  2. Hutter RV, Worcester JN Jr, Francis KS, Foote FW Jr, Stewart FW. Benign and malignant giant cell tumors of bone. A clinicopathological analysis of the natural history of the disease. Cancer. 1962;15:653–90.

    Article  CAS  PubMed  Google Scholar 

  3. Unni KK. Classification of bone tumours. Can J Surg. 1977;20:504–9.

    CAS  PubMed  Google Scholar 

  4. Rock MG, Sim FH, Unni KK, et al. Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients. J Bone Joint Surg. 1986;68A:1073–9.

    Google Scholar 

  5. Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer. 2003;97:2520–9.

    Article  PubMed  Google Scholar 

  6. Dahlin DC, Cupps RE, Johnson EW Jr. Giant-cell tumor: a study of 195 cases. Cancer. 1970;25:1061–70.

    Article  CAS  PubMed  Google Scholar 

  7. Anract P, De Pinieux G, Cottias P, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop. 1998;22:19–26.

    Article  CAS  PubMed  Google Scholar 

  8. Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature. Cancer. 1979;44:1393–402.

    Article  CAS  PubMed  Google Scholar 

  9. Carrasco CH, Murray JA. Giant cell tumors. Orthop Clin North Am. 1989;20:395–405.

    CAS  PubMed  Google Scholar 

  10. Huvos AG. Bone tumors: diagnosis, treatment, and prognosis. 2nd ed. Philadelphia: WB Saunders, 1991.

    Google Scholar 

  11. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg. 1987;69A:106–114.

    Google Scholar 

  12. Imsamran W, Leelawat K, Leelawat T, et al. Simple technique in the measurement of liver volume. J Med Assoc Thai. 2003;86:151–6.

    PubMed  Google Scholar 

  13. World Health Organization. International Classification of Functioning, Disability and Health. Geneva: World Health Organization, 2001.

    Google Scholar 

  14. Marcove RC, Miller TR, Cahan WC. The treatment of primary and metastatic bone tumors by repetitive freezing. Bull N Y Acad Med. 1968;44:532–44.

    CAS  PubMed  Google Scholar 

  15. Marcove RC, Miller TR. Treatment of primary and metastatic bone tumors by cryosurgery. JAMA. 1969;207:1890–4.

    Article  CAS  PubMed  Google Scholar 

  16. Cahan WG, Woodard HQ, et al. Sarcoma arising in irradiated bone: report of 11 cases. Cancer. 1948;1:3–29.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was funded in part by the United States of America State Department Fulbright Scholarship Program (S.D.) and the Major Family Fund for Musculoskeletal Oncology (J.H.). The authors acknowledge Andrew G. Huvos, MD (1934–2006), who diagnosed most of these cases and educated a generation of pathologists and orthopaedic surgeons.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John H. Healey MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Domovitov, S.V., Healey, J.H. Primary Malignant Giant-Cell Tumor of Bone Has High Survival Rate. Ann Surg Oncol 17, 694–701 (2010). https://doi.org/10.1245/s10434-009-0803-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0803-z

Keywords

Navigation